Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Marco Schiavo Lena

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3653-4111; OpenAlex author ID A5076163246. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 2, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2015: 1 trial · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 6 papers · 2024: 5 papers · 2025: 2 papers · 2026: 4 papers

Papers 21

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  3. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  4. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  5. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  6. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  7. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  8. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  9. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2↗
  10. Establishment of a Transplantation Model of PDAC-Derived Liver Metastases. Co-author DOI 10.1245/s10434-024-15514-3↗
  11. ASO Author Reflections: Bridging the Gap in PDAC Research: The Intraportal Model as a Platform for Studying Preclinical Liver Metastasis. Co-author DOI 10.1245/s10434-024-15655-5↗
  12. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  13. Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system. Co-author DOI 10.1007/s00428-023-03574-x↗
  14. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  15. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2023.104819↗
  16. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  17. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
  18. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). First author DOI 10.1245/s10434-022-11413-7↗
  19. ASO Author Reflections: Prognostic Index after Neoadjuvant Chemotherapy (PINC) in Pancreatic Ductal Adenocarcinoma as Novel Tumor Regression Grading System. First author DOI 10.1245/s10434-022-11461-z↗
  20. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic can… Co-author DOI 10.1016/j.ejso.2020.02.013↗
  21. Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. Co-author DOI 10.3390/cancers11070893↗

Trials 1

  1. A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer Principal investigator NCT04024358↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 17 shared papers, 2019–2026 · strength 2.94
  2. Stefano Crippa · 15 shared papers, 2019–2026 · strength 2.66
  3. Giulio Belfiori · 14 shared papers, 2019–2026 · strength 2.54
  4. Michele Reni · 12 shared papers, 2022–2026 · strength 2.25
  5. Stefano Partelli · 10 shared papers, 2020–2026 · strength 1.98
  6. Claudio Doglioni · 12 shared papers, 2019–2025 · strength 1.88
  7. Domenico Tamburrino · 9 shared papers, 2024–2026 · strength 1.88
  8. Giulia Gasparini · 10 shared papers, 2019–2026 · strength 1.83
  9. Federico De Stefano · 7 shared papers, 2024–2026 · strength 1.47
  10. Diego Palumbo · 7 shared papers, 2023–2026 · strength 1.39
  11. Nicolò Pecorelli · 6 shared papers, 2024–2026 · strength 1.27
  12. Paolo Riccardo Camisa · 6 shared papers, 2024–2026 · strength 1.26
  13. Francesco DE COBELLI · 6 shared papers, 2023–2026 · strength 1.20
  14. Miriam Redegalli · 4 shared papers, 2022–2023 · strength 0.79
  15. Gianpaolo Balzano · 5 shared papers, 2020–2026 · strength 0.74
  16. Maria Giulia Cangi · 4 shared papers, 2022–2025 · strength 0.67
  17. Paolo Giorgio Arcidiacono · 4 shared papers, 2022–2026 · strength 0.65
  18. Marina Macchini · 3 shared papers, 2023–2024 · strength 0.53
  19. Giulia Orsi · 3 shared papers, 2023–2024 · strength 0.53
  20. Erica Dugnani · 3 shared papers, 2023–2024 · strength 0.52
  21. Lorenzo Piemonti · 3 shared papers, 2023–2024 · strength 0.52
  22. Giuseppe Malleo · 2 shared papers, 2026 · strength 0.46
  23. Fabio Casciani · 2 shared papers, 2026 · strength 0.46
  24. Gabriella Lionetto · 2 shared papers, 2026 · strength 0.46
  25. Claudio Luchini · 2 shared papers, 2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.